Navigation Links
GE Healthcare to evaluate and develop novel imaging technology
Date:12/28/2009

A novel molecular imaging technology aimed at rapid diagnosis of cell death in organs such as the brain and heart has been licensed by The Medical College of Wisconsin to GE Healthcare. Under the license GE will further evaluate and develop the technology and will have an option to commercialize the technology. The technology, using imaging probes with a radiopharmaceutical compound, was invented by Ming Zhao, Ph.D., assistant professor of biophysics.

The probes bind to dead and dying cells making them useful for detecting acute cell injury and cell death. When the active component of this molecule is attached to a radioactive tracer, it can be used in nuclear medicine imaging techniques, such as PET (positron emission tomography) or SPECT (single photon emission computed tomography), to produce three-dimensional images of where this cell death is occurring.

"We are pleased to be working with GE on this technology," said Dennis Devitt, the director of marketing and licensing for the Office of Technology Development (OTD), the technology transfer arm of the Medical College. "Working with the market leader in medical imaging allows this technology to be quickly moved from the research laboratory into patient care," Devitt said.

According to Dr. Zhao, "Imaging agent discovery and development is an important aspect in molecular and medical imaging research. The process is critical for the improvement of existing imaging technologies and for early detection of acute cell death, cancerous tissue growth and major vessel diseases."

The ability to image dead and dying cells can have major clinical benefits, pointed out Dr. Zhao. For example, it could allow oncologists to rapidly monitor tumor response to a specific therapy. Another potential application is for rapid diagnosis of myocardial infarction. Often patients come into ER complaining of chest pain and need to have an expensive overnight hospital stay so they can be monitored while their lab results are being processed. This compound could allow clinicians to non-invasively image the heart and determine within a few hours if the patient actually had a heart attack or something else.

Joseph Hill, vice president for technology development, added that Dr. Zhao's research was supported by a "Proof-of-Concept" grant administered by the College's OTD. They have filed several patent applications on the technology.

The OTD patents intellectual property generated by faculty and staff at the Medical College and licenses it in line with its mission to commercialize as many inventions as possible to help patients. Its "Patents to PatientsSM" brand best describes its mission.


'/>"/>

Contact: Toranj Marphetia
toranj@mcw.edu
414-955-4744
Medical College of Wisconsin
Source:Eurekalert

Related biology news :

1. Conference to examine role technology can play in helping US manage healthcare costs
2. Hand hygiene initiative aims to decrease healthcare-associated infection in developing countries
3. Sangamo BioSciences to Present at the Bank of America 2008 Healthcare Conference
4. TGen, Scottsdale Healthcare, Mayo Clinic study new drug to stimulate immune system of cancer victims
5. Phoenix conference highlights TGens and Scottsdale Healthcares contributions to molecular oncology
6. TGen Clinical Research Services at Scottsdale Healthcare and Mayo Clinic study new cancer drug
7. GE Healthcare President & CEO, Mark Vachon, to Present at BioConference Live
8. Scott & White Healthcare researcher finds success with new anti-cancer drug
9. Scott & White Healthcare researcher finds success with new anti-cancer drug
10. Researchers to develop ocean sanctuary noise budget to evaluate potential impact on marine mammals
11. Promising new drug being evaluated as possible treatment option for fragile X syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample ... the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity ...
(Date:6/23/2016)... 2016 Andrew D ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... from touchONCOLOGY, Andrew D Zelenetz , discusses ... care is placing an increasing burden on healthcare ... therapies. With the patents on many biologics expiring, ...
Breaking Biology Technology: